The Chagas Heart Disease, described for the first time in 1909 by Carlos Chagas, is
caused by Trypanosoma cruzi, a flagellated protozoa transmitted to
humans, mostly by the feces of Triatoma infestans in endemic areas. Estimates are that
fifteen million people are infected in Latin America, leading to 45,000 deaths per year,
90% owing to heart disease.The cardiac involvement is the most prevalent and severe manifestation of Chagas Heart
Disease. After the infection, most individuals remain without manifestation of the
disease along their lives, but at least 30% develop heart rhythm disorders, severe
symptoms of heart failure and thromboembolic events, typically after 10-30 years after
infection. Chronic myocarditis predisposes to cardiac dilation and to the formation of
ventricular aneurysms. Thrombi are more prevalent in apical ventricular aneurysm, which
is typical of the disease, and the cause for thromboembolic events in the systemic and
pulmonary circulation. Segmental myocardial fibrosis is the anatomical substrate for
ventricular arrhythmias and atrio-ventricular and intraventricular conduction
abnormalities. Sudden death occurs in 55-65% of the patients, at times in the absence of
prior cardiac symptoms. Death as a result of heart failure happens in 25-30%, and
cerebral or pulmonary embolism, in 10-15%[1-3].Ventricular extrasystoles are rather common in patients with Chagas Heart Disease, and
its prevalence and complexity are associated with the extent of myocardial injury,
particularly with left ventricular dysfunction and dilation[4]. Non-sustained ventricular tachycardia (NSVT) has been
recognized as an independent risk factor for death and included in score for risk
stratification[5]. Sustained
ventricular tachycardia (SVT) is considered the main cause of sudden death, and may
happen in different stages of the disease and even in patients without important
ventricular dysfunction[6].Amiodarona is the most commonly used antiarrhythmic drug in Brazil to treat ventricular
arrhythmias in patients with Chagas Heart Disease. Cohort studies involving patients
with sustained Chagas Heart Disease and VT revealed 5-11.9% of annual mortality, with
sudden death representing 61-78% of the cases, mostly with important ventricular
systolic dysfunction[7-10]. On account of this, the implantable cardioverter
defibrillator (ICD) has been recommended to patients with sustained VT and ventricular
dysfunction[11-14]. However, patients with Chagas Heart Disease seem to
receive more ICD shocks compared to patients with coronary heart disease. A relevant
finding was the annual mortality of 16.6% in a cohort of 90 patients with Chagas Heart
Disease subject to ICD implantation due to sustained VT. Although the patients presented
low rate of sudden death, they had a significant rate of total mortality. Patients with
more than four shocks over a period of 30 days presented higher mortality compared to
patients with no shock or a smaller number[11]. Since these patients mostly died from heart failure, one can
speculate that excessive shocks applied by ICD may depress the ventricular function and
increase non-sudden mortality. This data corroborate the indication of catheter ablation
as the logical strategy to reduce the recurrence of sustained VT and prevent ICD
shocks[15].
Catheter Ablation of Sustained VT in Chagas Heart Disease
The main mechanism of SVT of chronic Chagas Heart Disease is the reentry located in a
left ventricle inferolateral and baseline scar in more than 70% of the
cases[16,17]. The reentrant circuit of SVT may involve
subendocardial, intramyocardial and subepicardial fibers. In some patients, the
reentrant circuits have their genesis in places with very thin walls and, on account
of that, conventional pulses of RF, emitted from the endocardium, may cause
transmural injury and reach all the structures potentially involved in the circuit.
Nevertheless, in others, the segmental injury is intramural and the circuit is
predominantly kept by subepicardial fibers. Insofar as the contralateral
subendocardial tissue is very thick, it may prevent RF applications from reaching
the causative intramyocardial and subepicardial fibers and be the reason for an
unsuccessful procedure. This was the initial hypothesis for resorting to the
transthoracic subxiphoid percutaneous approach to explore the pericardial space and
identify patients with possible subepicardial circuits[15].
Epicardial Ablation of Sustained VT in Chagas Heart Disease
The transthoracic epicardial approach has been used since 1995 for mapping and
ablation of sustained VT in patients with Chagas Heart Disease[18] and subsequently also applied in
patients with other heart diseases[19]. The experience acquired over time confirmed the initial
findings[20-23], and consensus documents issued by different
medical societies report that it is necessary in at least 20% of the patients
subject of SVT ablation in tertiary centers, mainly in patients with non-ischemic
heart diseases[24,25]. Recent review underscores the current importance
of the subxiphoid percutaneous approach in several intrapericardial
procedures[26].The technique of access to the periocardial space has been kept virtually unchanged
over time, with nearly no technological advance for its performance[27]. The Tuohy needle is the main tool
to reach the pericardial space (Figure 1). It
is curved at one end, which makes it easier to penetrate pericardial membranes
(Figure 2). A risk of 10% of pericardial
bleeding is forecasted when applying this technique, usually a minor and transient
one. The risk of severe bleeding demanding surgical repair is around 1-2%. In most
patients subject to this approach, the epicardial mapping widens the exploration
area. Pericardial adhesions are not common after prior ablations either.
Figure 1
Access to the normal pericardial space for epicardial mapping and ablation by
subxiphoid puncture. In detail, the Tuhoy needle drawn for epidural
anesthesia and used in this procedure to mitigate the risk of cardiac
perforation.
Figure 2
Technique of access to the normal pericardial space. A: Subxiphoid puncture
with Tuhoy needle. The epigastric compression makes it easier to introduce
the needle in the pericardial space, lowering the risk of intra-abdominal
organ perforation, mainly the liver. B: Heart fluoroscopy in left anterior
oblique projection (LAO) showing the right positioning of the guide wire in
the pericardial space. C, D, E: Fluoroscopic aspects in right anterior
oblique (RAO) and LAO of the positioning of the exploratory catheter on the
heart epicardial surface.
Access to the normal pericardial space for epicardial mapping and ablation by
subxiphoid puncture. In detail, the Tuhoy needle drawn for epidural
anesthesia and used in this procedure to mitigate the risk of cardiac
perforation.Technique of access to the normal pericardial space. A: Subxiphoid puncture
with Tuhoy needle. The epigastric compression makes it easier to introduce
the needle in the pericardial space, lowering the risk of intra-abdominal
organ perforation, mainly the liver. B: Heart fluoroscopy in left anterior
oblique projection (LAO) showing the right positioning of the guide wire in
the pericardial space. C, D, E: Fluoroscopic aspects in right anterior
oblique (RAO) and LAO of the positioning of the exploratory catheter on the
heart epicardial surface.The electrophysiological signs obtained during the epicardial mapping show patterns
similar to those obtained with the endocardial mapping, whether in patients with
Chagas Heart Disease or with other heart diseases. Delayed potentials are most
predominantly found in the target area during mapping in sinus rhythm and
pre-systolic activity. Meso-diastolic and continuous activities are also frequent in
the original place of VT. The critical isthmus of the reentrant circuit in the
subepicardial tissue may be confirmed by entrainment maneuvers or interruption of VT
during the application of RF in these places, as can be observed by the endocardial
approach. The prevalence of epicardial VT in 257 consecutive patients was higher in
patients with Chagas Heart Disease (37%) compared to patients after myocardial
infarction (28%) and patients with idiopathic dilated cardiomyopathy (24%)[28].Three anatomical aspects of the epicardial surface may hamper the efficiency of
epicardial ablation: the presence of epicardial coronary artery, a thick layer of
fat and the risk of causing injury in neighboring tissues, such as the phrenic
nerve[29]. For all these
reasons and more, a substantial number of patients still present clinical
recurrences after endocardial and epicardial ablation, whether due to limitations
found during the procedure or to the evolution of the disease. The recurrence rate
seems to decrease after the introduction of electroanatomic mapping to establish the
scar extension and limits (Figures 3 and 4), and irrigated-tip catheter ablations (deeper
injuries, even in the presence of fat) may bring on wider substrate
injuries[30]. Alternatively,
wider epicardial injuries may increase the risk of damaging the coronary arteries
and extracardiac structures[31,32].
Figure 3
Electroanatomic mapping in patients with Sustained Ventricular Tachycardia
(SVT) secondary to Chronic Chagas’ Cardiomyopathy (CCC). A: ECG in sinus
rhythm. Note that there are no disturbances of the atrioventricular and
intraventricular conduction or electrically inactive areas, but only change
of repolarization of the left ventricle (LV) inferior and lateral walls,
secondary to the segmental scar located in the same regions (panels C and
D). B: ECG of SVT with electrocardiographic pattern suggesting origin in the
LV baseline region (positive QRS of V1 to V6), with onset of ventricular
activation on the lateral wall (negative QRS in DI and aVL and positive in
D2, D3 and aVF). C: 3D electroanatomic mapping of the LV endocardial and
epicardial surfaces in sinus rhythm with the Carto system. The colors
represent the amplitude of the ventricular electrograms in the investigated
regions. Note that the low-voltage area, suggesting the presence of scar, is
predominantly epicardial. D: Integration of the endocardium and epicardium
maps showing the LV inferior lateral and baseline segmental injury,
anatomical substrate for SVT in this patient.
Figure 4
SVT ablation in the same patient of Figure
3. A: Electrophysiological scan documenting the moment of
application of RF pulse by epicardial catheter with interrupts SVT and
restores the sinus rhythm. I, II, III, V1 and V6: ECG leads synchronized
with intracavitary electrograms. RV p and RV d: bipolar electrograms
obtained by proximal and distal electrode placements of the right ventricle,
respectively. LV epi p and LV epi d: bipolar electrograms obtained,
respectively, by proximal and distal electrodes of the epicardial catheter
positioned on the LV inferior and lateral scar. VE endo p: bipolar sign of
the catheter introduced in the LV. RF: moment of application of radio
frequency power, which interrupts SVT. The application is kept by 60
seconds. Speed of registration: 25 mm/s. B: Posterior view of the voltage
electroanatomic map showing the limits of LV inferior, lateral and baseline
scar. The purple and pink spots indicate places with fractionated and
delayed electrograms during the sinus rhythm. The green spots indicate the
transition between the left ventricle and left atrium. C: Same
electroanatomic mapping view showing the RF applications (red spots) in the
SVT origin site.
Electroanatomic mapping in patients with Sustained Ventricular Tachycardia
(SVT) secondary to Chronic Chagas’ Cardiomyopathy (CCC). A: ECG in sinus
rhythm. Note that there are no disturbances of the atrioventricular and
intraventricular conduction or electrically inactive areas, but only change
of repolarization of the left ventricle (LV) inferior and lateral walls,
secondary to the segmental scar located in the same regions (panels C and
D). B: ECG of SVT with electrocardiographic pattern suggesting origin in the
LV baseline region (positive QRS of V1 to V6), with onset of ventricular
activation on the lateral wall (negative QRS in DI and aVL and positive in
D2, D3 and aVF). C: 3D electroanatomic mapping of the LV endocardial and
epicardial surfaces in sinus rhythm with the Carto system. The colors
represent the amplitude of the ventricular electrograms in the investigated
regions. Note that the low-voltage area, suggesting the presence of scar, is
predominantly epicardial. D: Integration of the endocardium and epicardium
maps showing the LV inferior lateral and baseline segmental injury,
anatomical substrate for SVT in this patient.SVT ablation in the same patient of Figure
3. A: Electrophysiological scan documenting the moment of
application of RF pulse by epicardial catheter with interrupts SVT and
restores the sinus rhythm. I, II, III, V1 and V6: ECG leads synchronized
with intracavitary electrograms. RV p and RV d: bipolar electrograms
obtained by proximal and distal electrode placements of the right ventricle,
respectively. LV epi p and LV epi d: bipolar electrograms obtained,
respectively, by proximal and distal electrodes of the epicardial catheter
positioned on the LV inferior and lateral scar. VE endo p: bipolar sign of
the catheter introduced in the LV. RF: moment of application of radio
frequency power, which interrupts SVT. The application is kept by 60
seconds. Speed of registration: 25 mm/s. B: Posterior view of the voltage
electroanatomic map showing the limits of LV inferior, lateral and baseline
scar. The purple and pink spots indicate places with fractionated and
delayed electrograms during the sinus rhythm. The green spots indicate the
transition between the left ventricle and left atrium. C: Same
electroanatomic mapping view showing the RF applications (red spots) in the
SVT origin site.Prospective randomized study is required to evaluate the role and risks of different
strategies during catheter ablations in patients with Chagas Heart Disease[33-38]. However, there is a special group of patients to whom
catheter ablation presents arguable benefits: patients with ICD receiving multiple
shocks, regardless of the adjuvant therapy with antiarrhythmic drugs. In these
cases, the clinical outcomes are very clear in short and medium-term
evaluations[39]. It is worth
noting that the Chagas Heart Disease has a progressive nature, and it is not
uncommon for patients with good left ventricular function to have favorable SVT
ablations, but return 5-10 years afterwards presenting left ventricular dysfunction
and recurrence of new SVT.
Authors: Luiz R Leite; Guilherme Fenelon; Aloyr Simoes; Georgia G Silva; Paul A Friedman; Angelo A V de Paola Journal: J Cardiovasc Electrophysiol Date: 2003-06
Authors: Edmond M Cronin; Frank M Bogun; Philippe Maury; Petr Peichl; Minglong Chen; Narayanan Namboodiri; Luis Aguinaga; Luiz Roberto Leite; Sana M Al-Khatib; Elad Anter; Antonio Berruezo; David J Callans; Mina K Chung; Phillip Cuculich; Andre d'Avila; Barbara J Deal; Paolo Della Bella; Thomas Deneke; Timm-Michael Dickfeld; Claudio Hadid; Haris M Haqqani; G Neal Kay; Rakesh Latchamsetty; Francis Marchlinski; John M Miller; Akihiko Nogami; Akash R Patel; Rajeev Kumar Pathak; Luis C Saenz Morales; Pasquale Santangeli; John L Sapp; Andrea Sarkozy; Kyoko Soejima; William G Stevenson; Usha B Tedrow; Wendy S Tzou; Niraj Varma; Katja Zeppenfeld Journal: J Interv Card Electrophysiol Date: 2020-10 Impact factor: 1.900
Authors: Edmond M Cronin; Frank M Bogun; Philippe Maury; Petr Peichl; Minglong Chen; Narayanan Namboodiri; Luis Aguinaga; Luiz Roberto Leite; Sana M Al-Khatib; Elad Anter; Antonio Berruezo; David J Callans; Mina K Chung; Phillip Cuculich; Andre d'Avila; Barbara J Deal; Paolo Della Bella; Thomas Deneke; Timm-Michael Dickfeld; Claudio Hadid; Haris M Haqqani; G Neal Kay; Rakesh Latchamsetty; Francis Marchlinski; John M Miller; Akihiko Nogami; Akash R Patel; Rajeev Kumar Pathak; Luis C Sáenz Morales; Pasquale Santangeli; John L Sapp; Andrea Sarkozy; Kyoko Soejima; William G Stevenson; Usha B Tedrow; Wendy S Tzou; Niraj Varma; Katja Zeppenfeld Journal: Europace Date: 2019-08-01 Impact factor: 5.214
Authors: R M Kulchetscki; C F Pisani; F K B Alexandre; M P Mayrink; A P Ferraz; F C Gouvea; A L M Goncalves; C A Hardy; S L Melo; M O Chokr; M I Scanavacca Journal: J Interv Card Electrophysiol Date: 2021-05-08 Impact factor: 1.900
Authors: David Santacruz; Fernando Rosas; Carina Abigail Hardy; Diego Ospina; Andrea Nathalie Rosas; Juan Manuel Camargo; Juan José Bermúdez; Juan Felipe Betancourt; Víctor Manuel Velasco; Mario D González Journal: Heart Rhythm O2 Date: 2021-12-17
Authors: Tereza Augusta Grillo; Guilherme Rafael S Athayde; Ana Flávia L Belfort; Reynaldo C Miranda; Andrea Z Beaton; Bruno R Nascimento Journal: Case Rep Cardiol Date: 2015-11-08